Pharmacogenetics of morphine: Potential implications in sickle cell disease

Am J Hematol. 2008 Mar;83(3):233-6. doi: 10.1002/ajh.21027.


Morphine is frequently used to treat painful episodes associated with sickle cell disease (SCD) but may fail to provide adequate analgesia in many patients. This concise review focuses on unique disease related changes in physiologic variables associated with SCD that impacts pharmacokinetics and pharmacodynamics of morphine and may contribute to the variability in analgesia. Emerging evidence suggests that the allelic variants in the genes involving the opioid (UGT2B7, OPRM1, and ABCB1 genes) and nonopioid system (COMT gene) can alter the efficacy of morphine.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anemia, Sickle Cell / drug therapy*
  • Anemia, Sickle Cell / genetics*
  • Genetic Variation
  • Glucuronides / pharmacokinetics
  • Humans
  • Morphine / pharmacokinetics*
  • Morphine / therapeutic use*
  • Pharmacogenetics


  • Glucuronides
  • Morphine